CBS 2019
CBSMD教育中心
English

双重抗血小板治疗持续时间

科研文章

荐读文献

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Individualized antiplatelet therapy after drug-eluting stent deployment: Implication of clinical trials of different durations of dual antiplatelet therapy Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel) Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysis Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy JACC Guideline Comparison: JACC State-of-the-Art Review Prasugrel versus clopidogrel in patients with acute coronary syndromes

Review Article2020 Jul 1;9(7):E2064.

JOURNAL:J Clin Med . Article Link

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective

G Tersalvi, L Biasco, GM Cioffi et al. Keywords: P2Y12 inhibition; acute coronary syndrome; bleeding; clopidogrel; dual antiplatelet therapy; high bleeding risk; prasugrel; tailored therapy; ticagrelor

Full Text PDF